

Eawag Überlandstrasse 133 8600 Dübendorf Switzerland Phone +41 (0)58 765 53 61 Fax +41 (0)58 765 53 75 info@eawag.ch www.eawag.ch

Eawag Seminar Invitation

Alternatives to animal testing in the 21st century

Speaker **Prof. Thomas Hartung** John Hopkins University, Baltimore, USA

When May 24, 11.00 – 12.00 a.m. Where Forum Chriesbach, room C20, Eawag Dübendorf

Abstract Increasingly, the limitations of animal-based toxicology to predict human health threats are recognized. However, we also recognize more and more shortcomings of traditional (human) cell culture. These include cell identity, differentiation, genetic stability and mycoplasma infection as well as non-homeostatic and non-physiological culture conditions. The increasing pace of technological developments of modern cell culture and their integration leads to what is called "disruptive technologies". The development of alternatives to traditional approaches for product development and safety assessment benefits from this. The creation of large toxicological databases ("big data") and data-mining technologies ("artificial intelligence") allow predictive computational approaches on a new scale. As an example, our new automated read-across (RASAR, i.e. read-across-based structure activity relationships) is given. At the same time, the combination of cell culture with bioengineering has led to a number of technologies to make cell culture more organo-typic, such as 3D culture, human stem cell-derived systems, perfusion, co-cultures, combinations with scaffolds and sensors etc.. Increasingly, they lead to "organ-on-chip" or even multi-organ "human-on-chip" solutions. By recreating organ architecture, homeostasis of the cell environment and organ functionality, these models mirror more closely the physiological situation. The example of our human iPSC-derived minibrain is used to illustrate this. The commercial availability of organoids also improves standardization and reproducibility.

Such technological advances promise to be real "game-changers". Combined with an increased mechanistic base of reasoning (e.g. Adverse Outcome Pathway concepts), Integrated Testing Strategies and evidence-based methods of data evaluation and integration, a revolutionary change for how we assess the biological effects of substances has been set into motion.